Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): Effects on intracellular calcium and platelet aggregation

Cardiovascular Drugs and Therapy

Volumn 9, Issue 6, 1995, Pages 815-821

  Hahn, Martina ^a   Tkachuk, Vsevolod A ^b   Bochkov, Valery N ^b   Cheglakov, Ivan B ^b   Clozel, Jean Paul ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

BAPTA; fura 2; human platelets; mibefradil; receptor operated calcium channels; voltage operated calcium channels

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FURA 2; MIBEFRADIL; PHORBOL 13 ACETATE 12 MYRISTATE; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

BENZIMIDAZOLES; BLOOD PLATELETS; CALCIUM; CALCIUM CHANNEL BLOCKERS; EGTAZIC ACID; HUMANS; MIBEFRADIL; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; TETRAHYDRONAPHTHALENES;

EID: 0029612325     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/BF00879876     Document Type: Article

References (27)

1. Selective inhibition of T-type Ca2+ channels by Ro 40-5967
2. Ro 40-5967: A new nondihydropyridine calcium antagonist
3. Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine
4. The effect of calcium channel blockers on blood platelet function, especially calcium uptake
5. Stimulation of calcium uptake by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (plateletactivating factor) in rabbit platelets: Possible involvement of the lipoxygenase pathway
6. Platelet aggregation and endogenous 5-HT secretion in presence of Ca2+, Sr2+ and Ba2+. Effects of calcium antagonists
7. Effects of nifedipine (Adalat®) on platelet function in vitro and in vivo
8. Phospholipid-induced human platelet activation: Effects of calcium channel blockers and calcium chelators
9. Effects of verapamil on platelet aggregation, ATP release and thromboxane generation
10. Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers
11. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets
12. Effect of calcium and calcium antagonists on [3H]-PAF-acether binding to washed human platelets
13. Absence of (−)[3H]desmethoxyverapamil binding sites on human platelets and lack of evidence for voltage-dependent calcium channels
14. Evidence for the receptor-operated calcium channels in human platelet plasma membrane
15. Calcium homeostasis in intact lymphocytes: Cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator
16. A new generation of Ca2+ indicators with greatly improved fluorescence properties
17. Platelet aggregation: The use of optical density fluctuations to study microaggregate formation in platelet suspension
18. Stimulation of non-selective cation channels providing Ca2+ influx into platelets by platelet-activating factor and other aggregation inducers
19. Agonists stimulate divalent cation channels in the plasma membrane of human platelets
20. Effects of ionic substitution on [Ca2+]1 rises evoked by thrombin and PAF in human platelets
21. Cytoplasmic Ca2+ is necessary for thrombin-induced platelet activation
22. Detection of ligand-activated conductive Ca2+ channels in human B lymphocytes
23. New calcium indicators and buffers with high selectivity against magnesium and protons: Design, synthesis, and properties of prototype structures
24. Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors
25. Hemodynamic and humoral effects of the novel calcium antoagonist Ro 40-5967 in patients with hypertension
26. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris